INS and type 2 diabetes mellitus: Despite numerous cardiovascular benefits associated with statin therapy in subjects with impaired glucose homeostasis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors slightly increase the risk of type 2 diabetes, probably because exerting an unfavorable effect on insulin sensitivity and secretion [28].